Banish the Brexit blues and come to Brussels, life sciences companies told

13 March 2019
belgium-big

As the UK government struggles to retain some semblance of an orderly Brexit, the city that houses the headquarters of the European Union (EU) has offered British-based businesses a route to allow them to operate seamlessly across the UK and European Union (EU) post-Brexit.

On Wednesday, the regional government for Brussels launched a campaign to attract businesses to set up a base in or around the Belgian capital, saying that if offers them an ideal place for a European base of operations post-Brexit.

The UK pharmaceutical sector has long been considered one of the jewels in the crown of British industry but it faces serious challenges in maintaining easy access to the European market following Brexit, and among those already moving its EU base to continental Europe is Shionogi (TYO: 4507).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight





More Features in Pharmaceutical